Market News

Bristol (BMY) Holder Benchmark Capital Advisors Trimmed Holding by $355,950 as Shares Declined; Jaffetilchin Investment Partners Trimmed Facebook (FB) Holding as Market Valuation Declined

Facebook, Inc. (NASDAQ:FB) Logo

Benchmark Capital Advisors decreased its stake in Bristol (BMY) by 6.57% based on its latest 2018Q1 regulatory filing with the SEC. Benchmark Capital Advisors sold 5,650 shares as the company’s stock declined 23.11% with the market. The institutional investor held 80,350 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $5.08 million, down from 86,000 at the end of the previous reported quarter. Benchmark Capital Advisors who had been investing in Bristol for a number of months, seems to be less bullish one the $88.24 billion market cap company. The stock decreased 0.49% or $0.265 during the last trading session, reaching $53.985. About 2.80 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 2.98% since June 21, 2017 and is downtrending. It has underperformed by 15.55% the S&P500. Some Historical BMY News: 26/04/2018 – Bristol-Myers Sees 2018 Worldwide Rev Increasing in the Mid-Single Digits; 31/05/2018 – Phase l/Il Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting; 18/05/2018 – FDA – MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS; 23/03/2018 – MERCY INVESTMENT SERVICES – AT BRISTOL-MYERS SHAREHOLDERS’ MEETING, SHAREHOLDERS WILL HAVE CHANCE TO VOTE ON PROPOSAL SPONSORED BY MULTIPLE SHAREHOLDERS; 16/04/2018 – Rhode Island DoA: Bristol Fourth of July Committee Mon, 4/16/2018, 8:00 PM; 26/04/2018 – BMY SEES 1L LUNG TO BE CHALLENGE BECAUSE OF COMPETITORS; 16/04/2018 – Bristol-Myers: Combo Shows Superior Benefit for Co-Primary Endpoint of Progression-Free Survival; 16/04/2018 – So now embargo times may be shifting $BMY; 26/04/2018 – BRISTOL-MYERS SQUIBB CO BMY.N SEES FY 2018 GAAP SHR $2.70 TO $2.80; 25/04/2018 – Rhode Island DoA: Bristol Substance Abuse Prevention Task Force Wed, 4/25/2018, 10:30 AM

Jaffetilchin Investment Partners Llc decreased its stake in Facebook Inc (FB) by 9.27% based on its latest 2018Q1 regulatory filing with the SEC. Jaffetilchin Investment Partners Llc sold 2,785 shares as the company’s stock declined 0.01% with the market. The institutional investor held 27,271 shares of the technology company at the end of 2018Q1, valued at $4.36 million, down from 30,056 at the end of the previous reported quarter. Jaffetilchin Investment Partners Llc who had been investing in Facebook Inc for a number of months, seems to be less bullish one the $587.96B market cap company. The stock increased 0.55% or $1.12 during the last trading session, reaching $203.12. About 12.46M shares traded. Facebook, Inc. (NASDAQ:FB) has risen 21.69% since June 21, 2017 and is uptrending. It has outperformed by 9.12% the S&P500. Some Historical FB News: 24/04/2018 – Facebook Earnings, for One Quarter, Could Offer Respite — Barron’s Blog; 14/03/2018 – Facebook is talking with news outlets about creating daily videos for Facebook Watch; 20/03/2018 – U.K. Seeks Search Warrant for Cambridge Analytica After Facebook Data Scandal; 01/05/2018 – BlueJeans Announces Latest Integration with Workplace by Facebook; 15/05/2018 – Canbiola, Inc. (OTC PINK: CANB) Announces New National Distribution Partnership with Strategic Medical Re; 22/05/2018 – Exclusive: EU warns that Facebook’s Cambridge Analytica crisis is the ‘tip of an iceberg’ of data scandals; 13/04/2018 – Poverty with a human face and a Facebook page; 24/04/2018 – FB HIRING MORE TO REVIEW ADS, BUILDING BETTER SYSTEMS REVIEW; 19/03/2018 – Facebook Security Chief To Exit: Report — MarketWatch; 03/05/2018 – Facebook’s developer conference showed that Facebook is still Facebook:

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. Jefferies maintained Bristol-Myers Squibb Company (NYSE:BMY) on Thursday, November 16 with “Hold” rating. The company was upgraded on Friday, January 22 by Berenberg. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Wednesday, August 16. BMO Capital Markets has “Sell” rating and $49.0 target. The firm earned “Equal-Weight” rating on Friday, August 5 by Morgan Stanley. The firm has “Hold” rating given on Friday, October 28 by Deutsche Bank. Citigroup maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Wednesday, October 18. Citigroup has “Buy” rating and $72 target. As per Monday, October 23, the company rating was maintained by Leerink Swann. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Thursday, August 27. As per Friday, September 22, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating given on Tuesday, April 17 by Guggenheim.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers’ Opdivo + Yervoy beats Pfizer’s Sutent in late-stage RCC study” on June 01, 2018, also Forbes.com with their article: “How Sensitive Is Bristol-Myers Squibb To Its R&D Expense Change?” published on June 05, 2018, Seekingalpha.com published: “Merck up 2% premarket on positive Keytruda data; Bristol-Myers down 2%” on June 04, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Streetinsider.com and their article: “Bristol-Myers Squibb (BMY) Says China National Drug Administration Approved Country’s First Immuno-Oncology …” published on June 15, 2018 as well as Seekingalpha.com‘s news article titled: “Bristol-Myers Top NASH Contenders” with publication date: June 12, 2018.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on July, 26. They expect $0.87 EPS, up 17.57% or $0.13 from last year’s $0.74 per share. BMY’s profit will be $1.42B for 15.51 P/E if the $0.87 EPS becomes a reality. After $0.94 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -7.45% negative EPS growth.

Since April 30, 2018, it had 1 buying transaction, and 0 selling transactions for $249,948 activity.

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.11, from 0.94 in 2017Q4. It fall, as 64 investors sold BMY shares while 573 reduced holdings. 111 funds opened positions while 418 raised stakes. 1.12 billion shares or 1.08% more from 1.11 billion shares in 2017Q4 were reported. Nelson Roberts Investment Advsr Limited Liability Corporation stated it has 1.42% in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, Alphaone Ser Limited Liability has 0.08% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 4,455 shares. Pdts Ptnrs Lc invested in 0.5% or 234,430 shares. The Massachusetts-based Nichols Pratt Advisers Llp Ma has invested 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). Parthenon Ltd Liability Co has invested 0.16% in Bristol-Myers Squibb Company (NYSE:BMY). Abner Herrman Brock Ltd Llc accumulated 8,735 shares. Sabal Tru holds 2.59% in Bristol-Myers Squibb Company (NYSE:BMY) or 428,660 shares. 4,050 are owned by Savings Bank Of Nova Scotia Trust. Newman Dignan & Sheerar stated it has 0.87% in Bristol-Myers Squibb Company (NYSE:BMY). Independent Invsts Inc reported 1.14% stake. Moreover, Zeke Cap Advsrs Lc has 0.26% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 43,927 shares. Boyer And Corporon Wealth Mgmt Limited Company has 56,275 shares for 1.51% of their portfolio. Adage Prtnrs Grp Ltd Liability Company invested in 0.4% or 2.73M shares. One Mgmt Ltd Liability stated it has 0.47% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Lee Danner And Bass owns 45,341 shares.

Benchmark Capital Advisors, which manages about $225.46 million and $126.50M US Long portfolio, upped its stake in Kkr & Co LP Del Com Units (NYSE:KKR) by 15,540 shares to 170,513 shares, valued at $3.46M in 2018Q1, according to the filing.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on July, 25. They expect $1.72 earnings per share, up 30.30% or $0.40 from last year’s $1.32 per share. FB’s profit will be $4.98 billion for 29.52 P/E if the $1.72 EPS becomes a reality. After $1.69 actual earnings per share reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts 1.78% EPS growth.

Among 55 analysts covering Facebook (NASDAQ:FB), 51 have Buy rating, 2 Sell and 2 Hold. Therefore 93% are positive. Facebook had 274 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, April 28 by Evercore. The company was maintained on Thursday, July 20 by William Blair. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Thursday, November 5 by Pivotal Research. The firm has “Buy” rating given on Monday, January 8 by Bank of America. The stock has “Buy” rating by Robert W. Baird on Thursday, November 30. BTIG Research upgraded the stock to “Buy” rating in Tuesday, March 21 report. The rating was maintained by SunTrust on Friday, January 12 with “Buy”. The firm has “Buy” rating by Wedbush given on Monday, November 6. Jefferies maintained it with “Buy” rating and $160 target in Thursday, April 28 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, July 21.

Since January 9, 2018, it had 0 insider purchases, and 70 selling transactions for $3.22 billion activity. $9.61 million worth of Facebook, Inc. (NASDAQ:FB) shares were sold by Sandberg Sheryl. 440,000 shares valued at $79.13M were sold by Zuckerberg Mark on Monday, March 5. Shares for $2.88M were sold by Stretch Colin. FISCHER DAVID B. had sold 17,830 shares worth $3.29 million on Tuesday, February 27. Wehner David M. had sold 4,761 shares worth $880,309 on Monday, May 21. Cox Christopher K had sold 10,600 shares worth $2.03 million on Monday, June 11.

Jaffetilchin Investment Partners Llc, which manages about $401.38M and $446.15M US Long portfolio, upped its stake in First Tr Excnge Trd Alphadex (FYC) by 11,067 shares to 18,546 shares, valued at $804,000 in 2018Q1, according to the filing. It also increased its holding in Opko Health Inc (NYSE:OPK) by 372,311 shares in the quarter, for a total of 1.32M shares, and has risen its stake in Nasdaq Inc (NASDAQ:NDAQ).

More notable recent Facebook, Inc. (NASDAQ:FB) news were published by: Nasdaq.com which released: “Facebook Inc (FB) Adds User Reviews for Ads to Identify Bad Businesses” on June 13, 2018, also Nasdaq.com with their article: “Facebook, Inc. (FB) to Design Chips for Live Video Content Filtering” published on May 29, 2018, Nasdaq.com published: “Trade of the Day: Facebook, Inc. (FB)” on June 19, 2018. More interesting news about Facebook, Inc. (NASDAQ:FB) were released by: Livetradingnews.com and their article: “Facebook, Inc. (NASDAQ:FB) just hit an all-time high” published on June 19, 2018 as well as Nasdaq.com‘s news article titled: “Facebook Stock Will Continue to Shrug Off Data Privacy Concerns” with publication date: June 05, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *